Navigating supply chains and product portfolios during a pandemic

By 2025, the global advanced therapy medicinal products (ATMP) sector, encompassing cell therapies, gene therapies, and genetically modified cell-based medicines, has progressed from early scientific success to clinical and commercial reality. Following a decade of...

In the European Union (EU), the release of medicinal products for commercial supply is a highly regulated activity. Central to this release process is the Qualified Person (QP), a legally defined role under EU pharmaceutical legislation. The QP is responsible for...

UK researchers said on Wednesday they have slowed the progression of the fatal neural condition Huntington's disease for the first time with a groundbreaking new gene therapy. Huntington's disease causes nerve cells in the brain to decay over time. The disease affects...